Literature DB >> 6619281

Determination of serum bactericidal activity with the aid of luminous bacteria.

M Barak, S Ulitzur, D Merzbach.   

Abstract

Nonmarine luminous bacteria belonging to the genus Vibrio cholerae were extremely sensitive to the bactericidal activity of human serum. Luminous bacteria incubated in a medium containing serum showed a decrease in their in vivo luminescence that was directly proportional to the decrease in the viable count and was a function of the serum concentration. Both immunoglobulins and the complement system were required to exert the serum bactericidal activity. Serum lacking immunoglobulins or certain complement components, especially C3, did not affect the luminescence. The bactericidal effect of the serum on luminous bacteria was diminished by the presence of lipopolysaccharide or by pretreatment of the serum with different species of killed bacteria. As found in other systems, the bacteriolytic activity of serum was only augmented by lysozyme, but was not lysozyme dependent; although the luminous bacteria were converted into spheroplasts in serum containing 0.5 M sucrose, their in vivo luminescence was almost not affected. This system could easily distinguish between the C classical pathway and the properdin pathway. Ethylene glycol-bis (beta-aminoethyl ether)-N,N'-tetraacetic acid, which inhibits only the classical complement pathway, did not inhibit the decrease in luminescence as did EDTA. Thus, it was possible to distinguish between deficiencies in complement components participating in both pathways and complement components that were involved only in the classical pathway. This system could also be used as a substitute to the hemolytic system in complement fixation tests.

Entities:  

Mesh:

Year:  1983        PMID: 6619281      PMCID: PMC270786          DOI: 10.1128/jcm.18.2.248-253.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Molecular and structural damage to Escherichia coli produced by antibody, complement, and lysozyme systems.

Authors:  L A Wilson; J K Spitznagel
Journal:  J Bacteriol       Date:  1968-10       Impact factor: 3.490

2.  A stable, inexpensive, solid-state photomultiplier photometer.

Authors:  G W Mitchell; J W Hastings
Journal:  Anal Biochem       Date:  1971-01       Impact factor: 3.365

3.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

4.  The complement system in uremia.

Authors:  K A Jørgensen; E Stoffersen
Journal:  Scand J Urol Nephrol       Date:  1980

5.  Defective activation of the third component of complement in the sera of newborn infants.

Authors:  J A Winkelstein; L E Kurlandsky; A J Swift
Journal:  Pediatr Res       Date:  1979-10       Impact factor: 3.756

6.  Sequential metabolic expressions of the lethal process in human serum-treated Escherichia coli: role of lysozyme.

Authors:  R J Martinez; S F Carroll
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

7.  Glomerular deposition of complement-control proteins in acute and chronic glomerulonephritis.

Authors:  R J Wyatt; A J McAdams; J Forristal; J Snyder; C D West
Journal:  Kidney Int       Date:  1979-10       Impact factor: 10.612

8.  Effects of serum components on gram-negative bacteria during bactericidal reactions.

Authors:  L Melching; S I Vas
Journal:  Infect Immun       Date:  1971-01       Impact factor: 3.441

9.  Human serum complement requirements for bacterial killing and protoplast lysis of Escherichia coli ML308 225.

Authors:  R J Allen; G K Scott
Journal:  J Gen Microbiol       Date:  1981-03

10.  Significance of serum complement levels in patients with gastrointestinal disease.

Authors:  I N Ross; R A Thompson; R D Montgomery; P Asquith
Journal:  J Clin Pathol       Date:  1979-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.